A Phase 2 interventional study of SYH2069 Injection and SYH2069 Injection Placebo in Overweight or Obesity, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment
To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 360 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →CSPC Ouyi Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SYH2069 dose 1 : SYH2069 Injection: dose level 1 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 2: SYH2069 Injection: dose level 2 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 3: SYH2069 Injection: dose level 3 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 4: SYH2069 Injection: dose level 4 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 5: SYH2069 Injection: dose level 5 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 6: SYH2069 Injection: dose level 6 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 7: SYH2069 Injection: dose level 7 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 8: SYH2069 Injection: dose level 8 for 28 weeks
Drug: SYH2069 Injection
SYH2069 Injection Placebo: Placebo arm matching active arm SYH2069 Injection dose level for 28 weeks
Drug: SYH2069 Injection Placebo
0.6ml , 1.2ml , administered subcutaneously (SC)，Administer the drug according to the clinical trial protocol
0.6ml , 1.2ml , SC，Administer the drug according to the clinical trial protocol
Relative percentage change in body weight from baseline at of treatment at 28 weeks of treatment
Time frame: 28 weeks
Proportion of subjects with a weight loss of ≥5% , 10%, 15% from baseline at 28 weeks of treatment
Time frame: Baseline through Week 28
Change from baseline in body Weight
Time frame: Week 2, 4, 8, 12, 16, 20, 24 and 28
Changes from baseline in waist circumference
Time frame: Baseline through Week 28
Changes from baseline in hip circumference
Time frame: Baseline through Week 28
Changes from baseline in waist-to-hip ratio
Time frame: Baseline through Week 28
Changes from baseline in Body Mass Index (BMI)
Time frame: Baseline through Week 28
Changes from baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline through Week 28
Changes from baseline in fasting plasma glucose (FPG)
Time frame: Baseline through Week 28
Changes from baseline in fasting C-peptide
Time frame: Baseline through Week 28
Changes from baseline in Homeostatic Model Assessment of Insulin Resistance(HOMA-IRs)
Time frame: Baseline through Week 28
Changes from baseline in systolic blood pressure
Time frame: Baseline through Week 28
Changes from baseline in diastolic blood pressure
Time frame: Baseline through Week 28
Changes from baseline in lipid parameters (TC, LDL-C, HDL-C, non-HDL-C, TG, ApoB)
Time frame: Baseline through Week 28
Changes from baseline in high sensitivity C reactive protein (hs-CRP)
Time frame: Baseline through Week 28
Changes from baseline in urinary albumin-to-creatinine ratio (UACR)
Time frame: Baseline through Week 28
The incidence rate of adverse events (AEs)
Time frame: Baseline through Week 31
Plasma concentrations & PK parameters: Peak Time (Tmax)
Time frame: Baseline through Week 31
Plasma concentrations & PK parameters: Peak Plasma Concentration (Cmax)
Time frame: Baseline through Week 31
Plasma concentrations & PK parameters: Area under the plasma concentration versus time curve(AUC) : AUClast, AUC0-168h, AUC0-336h
Time frame: Baseline through Week 31
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SYH2069
CSPC Ouyi Pharmaceutical Co., Ltd. →